-
1
-
-
84860449791
-
Current advances and perspectives in the treatment of advanced melanoma
-
Livingstone E, Zimmer L, Vaubel J, Schadendorf D,. Current advances and perspectives in the treatment of advanced melanoma. J Dtsch Dermatol Ges 2012; 10: 319-25.
-
(2012)
J Dtsch Dermatol Ges
, vol.10
, pp. 319-325
-
-
Livingstone, E.1
Zimmer, L.2
Vaubel, J.3
Schadendorf, D.4
-
2
-
-
84893339764
-
Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma
-
Pflugfelder A, Kochs C, Blum A, et al. Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma ". J Dtsch Dermatol Ges 2013; Suppl 6: 1-116.
-
(2013)
J Dtsch Dermatol Ges
, pp. 1-116
-
-
Pflugfelder, A.1
Kochs, C.2
Blum, A.3
-
3
-
-
33746562357
-
Immunotherapy of malignant melanoma - Basic principles and novel therapeutic approaches
-
Enk AH, Becker JC, Schuler G,. Immunotherapy of malignant melanoma-basic principles and novel therapeutic approaches. J Dtsch Dermatol Ges 2006; 4: 635-45.
-
(2006)
J Dtsch Dermatol Ges
, vol.4
, pp. 635-645
-
-
Enk, A.H.1
Becker, J.C.2
Schuler, G.3
-
4
-
-
33847615238
-
Dendritic cell-based immunotherapy of malignant melanoma: Success and limitations
-
Tuettenberg A, Schmitt E, Knop J, Jonuleit H,. Dendritic cell-based immunotherapy of malignant melanoma: success and limitations. J Dtsch Dermatol Ges 2007; 5: 190-6.
-
(2007)
J Dtsch Dermatol Ges
, vol.5
, pp. 190-196
-
-
Tuettenberg, A.1
Schmitt, E.2
Knop, J.3
Jonuleit, H.4
-
5
-
-
20944442315
-
Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: How can we tilt the balance towards immune-mediated cancer control
-
Rivoltini L, Canese P, Huber V, et al. Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control ? Expert Opin Biol Ther 2005; 5: 463-76.
-
(2005)
Expert Opin Biol Ther
, vol.5
, pp. 463-476
-
-
Rivoltini, L.1
Canese, P.2
Huber, V.3
-
6
-
-
33745365936
-
Tumor-stroma interactions: Their role in the control of tumor cell invasion and metastasis
-
Löffek S, Zigrino P, Mauch C,. Tumor-stroma interactions: their role in the control of tumor cell invasion and metastasis. J Dtsch Dermatol Ges 2006; 4: 496-502.
-
(2006)
J Dtsch Dermatol Ges
, vol.4
, pp. 496-502
-
-
Löffek, S.1
Zigrino, P.2
Mauch, C.3
-
7
-
-
84856727864
-
Novel insights into the molecular mechanisms of HLA class i abnormalities
-
Seliger B,. Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunol Immunother 2012; 61: 249-54.
-
(2012)
Cancer Immunol Immunother
, vol.61
, pp. 249-254
-
-
Seliger, B.1
-
8
-
-
34848819211
-
Failure at the effector phase: Immune barriers at the level of the melanoma tumor microenvironment
-
Gajewski TF,. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007; 13: 5256-61.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 5256-5261
-
-
Gajewski, T.F.1
-
9
-
-
48349102876
-
Macrophage polarization in tumour progression
-
Sica A, Larghi P, Mancino A, et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18: 349-55.
-
(2008)
Semin Cancer Biol
, vol.18
, pp. 349-355
-
-
Sica, A.1
Larghi, P.2
Mancino, A.3
-
10
-
-
79957834585
-
Regulatory dendritic cells: New targets for cancer immunotherapy
-
Shurin MR, Naiditch H, Zhong H, Shurin GV,. Regulatory dendritic cells: new targets for cancer immunotherapy. Cancer Biol Ther 2011; 11: 988-92.
-
(2011)
Cancer Biol Ther
, vol.11
, pp. 988-992
-
-
Shurin, M.R.1
Naiditch, H.2
Zhong, H.3
Shurin, G.V.4
-
12
-
-
84862153001
-
New insights into chronic inflammation-induced immunosuppression
-
Kanterman J, Sade-Feldman M, Baniyash M,. New insights into chronic inflammation-induced immunosuppression. Semin Cancer Biol 2012; 22: 307-18.
-
(2012)
Semin Cancer Biol
, vol.22
, pp. 307-318
-
-
Kanterman, J.1
Sade-Feldman, M.2
Baniyash, M.3
-
13
-
-
84862143053
-
Melanoma-induced immunosuppression and its neutralization
-
Umansky V, Sevko A,. Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol 2012; 22: 319-26.
-
(2012)
Semin Cancer Biol
, vol.22
, pp. 319-326
-
-
Umansky, V.1
Sevko, A.2
-
14
-
-
77955549860
-
Myeloid-derived suppressor cells: More mechanisms for inhibiting antitumor immunity
-
Ostrand-Rosenberg S,. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010; 59: 1593-600.
-
(2010)
Cancer Immunol Immunother
, vol.59
, pp. 1593-1600
-
-
Ostrand-Rosenberg, S.1
-
15
-
-
77951258918
-
Myeloid-derived suppressor cell heterogeneity and subset definition
-
Peranzoni E, Zilio S, Marigo I, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010; 22: 238-44.
-
(2010)
Curr Opin Immunol
, vol.22
, pp. 238-244
-
-
Peranzoni, E.1
Zilio, S.2
Marigo, I.3
-
16
-
-
84856706929
-
Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients
-
Filipazzi P, Huber V, Rivoltini L,. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 2012; 61: 255-63.
-
(2012)
Cancer Immunol Immunother
, vol.61
, pp. 255-263
-
-
Filipazzi, P.1
Huber, V.2
Rivoltini, L.3
-
17
-
-
84864474722
-
On the armament and appearances of human myeloid-derived suppressor cells
-
Poschke I, Kiessling R,. On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol 2012; 144: 250-68.
-
(2012)
Clin Immunol
, vol.144
, pp. 250-268
-
-
Poschke, I.1
Kiessling, R.2
-
18
-
-
75149179545
-
Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer
-
Pan PY, Ma G, Weber KJ, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010; 70: 99-108.
-
(2010)
Cancer Res
, vol.70
, pp. 99-108
-
-
Pan, P.Y.1
Ma, G.2
Weber, K.J.3
-
19
-
-
79952281184
-
Angiogenesis and immunity: A bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy
-
Tartour E, Pere H, Maillere B, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 2011; 30: 83-95.
-
(2011)
Cancer Metastasis Rev
, vol.30
, pp. 83-95
-
-
Tartour, E.1
Pere, H.2
Maillere, B.3
-
20
-
-
80054730389
-
Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model
-
Meyer C, Sevko A, Ramacher M, et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. PNAS U S A 2011; 108: 17111-6.
-
(2011)
PNAS U S A
, vol.108
, pp. 17111-17116
-
-
Meyer, C.1
Sevko, A.2
Ramacher, M.3
-
21
-
-
84875511757
-
Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation
-
Sade-Feldman M, Kanterman J, Ish-Shalom E,. Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity 2013; 38: 541-54.
-
(2013)
Immunity
, vol.38
, pp. 541-554
-
-
Sade-Feldman, M.1
Kanterman, J.2
Ish-Shalom, E.3
-
22
-
-
77950346282
-
Immunity, inflammation, and cancer
-
Grivennikov SI, Greten FR, Karin M,. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
-
(2010)
Cell
, vol.140
, pp. 883-899
-
-
Grivennikov, S.I.1
Greten, F.R.2
Karin, M.3
-
23
-
-
60749122560
-
Melanoma and innate immunity - Active inflammation or just erroneous attraction?: Melanoma as the source of leukocyte-attracting chemokines
-
Navarini-Meury AA, Conrad C,. Melanoma and innate immunity-Active inflammation or just erroneous attraction?: Melanoma as the source of leukocyte-attracting chemokines. Semin Cancer Biol 2009; 19: 84-91.
-
(2009)
Semin Cancer Biol
, vol.19
, pp. 84-91
-
-
Navarini-Meury, A.A.1
Conrad, C.2
-
24
-
-
70350558753
-
Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression
-
Johnson B, Osada T, Clay T,. Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression. Curr Mol Med 2009; 9: 702-7.
-
(2009)
Curr Mol Med
, vol.9
, pp. 702-707
-
-
Johnson, B.1
Osada, T.2
Clay, T.3
-
25
-
-
78650756969
-
Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function
-
Condamine T, Gabrilovich DI,. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 2011; 32: 19-25.
-
(2011)
Trends Immunol
, vol.32
, pp. 19-25
-
-
Condamine, T.1
Gabrilovich, D.I.2
-
26
-
-
70350500225
-
STATs in cancer inflammation and immunity: A leading role for STAT3
-
Yu H, Pardoll D, Jove R,. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 798-809
-
-
Yu, H.1
Pardoll, D.2
Jove, R.3
-
27
-
-
84897029294
-
Exosomes from RBC units bind to monocytes and induce pro-inflammatory cytokines, boosting T cell responses in vitro
-
Danesh A, Inglis HC, Jackman RP,. Exosomes from RBC units bind to monocytes and induce pro-inflammatory cytokines, boosting T cell responses in vitro. Blood 2014; 123: 687-96.
-
(2014)
Blood
, vol.123
, pp. 687-696
-
-
Danesh, A.1
Inglis, H.C.2
Jackman, R.P.3
-
28
-
-
0032560475
-
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice
-
Kaplan DH, Shankaran V, Dighe AS,. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998; 95: 7556-61.
-
(1998)
Proc Natl Acad Sci U S A
, vol.95
, pp. 7556-7561
-
-
Kaplan, D.H.1
Shankaran, V.2
Dighe, A.S.3
-
29
-
-
80053469514
-
The two faces of interferon-Î in cancer
-
Zaidi MR, Merlino G,. The two faces of interferon-Î in cancer. Clin Cancer Res 2011; 17: 6118-24.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 6118-6124
-
-
Zaidi, M.R.1
Merlino, G.2
-
30
-
-
33749488765
-
Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes
-
Valenti R, Huber V, Filipazzi P, et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res 2006; 66: 9290-8.
-
(2006)
Cancer Res
, vol.66
, pp. 9290-9298
-
-
Valenti, R.1
Huber, V.2
Filipazzi, P.3
-
31
-
-
56449092100
-
Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors
-
Umansky V, Abschuetz O, Osen W, et al. Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors. Cancer Res 2008; 68: 9451-8.
-
(2008)
Cancer Res
, vol.68
, pp. 9451-9458
-
-
Umansky, V.1
Abschuetz, O.2
Osen, W.3
-
32
-
-
67650354587
-
Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma
-
Zhao F, Falk C, Osen W,. Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin Cancer Res 2009; 15: 4382-90.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 4382-4390
-
-
Zhao, F.1
Falk, C.2
Osen, W.3
-
33
-
-
77954226431
-
Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs
-
Kimpfler S, Sevko A, Ring S, et al. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. J Immunol 2009; 183: 6330-7.
-
(2009)
J Immunol
, vol.183
, pp. 6330-6337
-
-
Kimpfler, S.1
Sevko, A.2
Ring, S.3
-
34
-
-
77953141534
-
Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign
-
Poschke I, Mougiakakos D, Hansson J,. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010; 70: 4335-45.
-
(2010)
Cancer Res
, vol.70
, pp. 4335-4345
-
-
Poschke, I.1
Mougiakakos, D.2
Hansson, J.3
-
35
-
-
84880294344
-
Vemurafenib reverses immunosuppression by myeloid derived suppressor cells
-
Schilling B, Sucker A, Griewank K, et al. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer 2013; 133: 1653-63.
-
(2013)
Int J Cancer
, vol.133
, pp. 1653-1663
-
-
Schilling, B.1
Sucker, A.2
Griewank, K.3
-
36
-
-
84896523495
-
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: Comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells
-
Weide B, Martens A, Zelba H, et al. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res 2014; 20: 1601-9.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 1601-1609
-
-
Weide, B.1
Martens, A.2
Zelba, H.3
-
37
-
-
84896523643
-
Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase 1 production
-
de Coana YP, Poschke I, Gentlcore G, et al. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase 1 production. Cancer Immunol Res 2013; 1: 158-62.
-
(2013)
Cancer Immunol Res
, vol.1
, pp. 158-162
-
-
De Coana, Y.P.1
Poschke, I.2
Gentlcore, G.3
-
38
-
-
78649674576
-
Targeting immune suppressing myeloid-derived suppressor cells in oncology
-
Kao J, Ko EC, Eisenstein S,. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol 2011; 77: 12-9.
-
(2011)
Crit Rev Oncol Hematol
, vol.77
, pp. 12-19
-
-
Kao, J.1
Ko, E.C.2
Eisenstein, S.3
-
39
-
-
38049181485
-
Reversion of immune tolerance in advanced malignancy: Modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function
-
Pan PY, Wang GX, Yin B, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008; 111: 219-28.
-
(2008)
Blood
, vol.111
, pp. 219-228
-
-
Pan, P.Y.1
Wang, G.X.2
Yin, B.3
-
40
-
-
65549141834
-
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies
-
Ozao-Choy J, Ma G, Kao J, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009; 69: 2514-22.
-
(2009)
Cancer Res
, vol.69
, pp. 2514-2522
-
-
Ozao-Choy, J.1
Ma, G.2
Kao, J.3
-
41
-
-
33749461167
-
All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients
-
Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006; 66: 9299-307.
-
(2006)
Cancer Res
, vol.66
, pp. 9299-9307
-
-
Mirza, N.1
Fishman, M.2
Fricke, I.3
-
42
-
-
58549103730
-
Combination of all-trans retinoic acid and a human papillomavirus therapeutic vaccine suppresses the number and function of immature myeloid cells and enhances antitumor immunity
-
Song X, Ye D, Liu B, et al. Combination of all-trans retinoic acid and a human papillomavirus therapeutic vaccine suppresses the number and function of immature myeloid cells and enhances antitumor immunity. Cancer Sci 2009; 100: 334-40.
-
(2009)
Cancer Sci
, vol.100
, pp. 334-340
-
-
Song, X.1
Ye, D.2
Liu, B.3
-
43
-
-
84862120892
-
Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner
-
Michels T, Shurin GV, Naiditch H,. Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J Immunotoxicol 2012; 9: 292-300.
-
(2012)
J Immunotoxicol
, vol.9
, pp. 292-300
-
-
Michels, T.1
Shurin, G.V.2
Naiditch, H.3
-
44
-
-
84860518841
-
Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice
-
Sevko A, Kremer V, Falk C, et al. Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice. J Immunotoxicol 2012; 9: 275-81.
-
(2012)
J Immunotoxicol
, vol.9
, pp. 275-281
-
-
Sevko, A.1
Kremer, V.2
Falk, C.3
-
45
-
-
84874232680
-
Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model
-
Sevko A, Michels T, Vrohlings M, et al. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J Immunol 2013; 190: 2464-71.
-
(2013)
J Immunol
, vol.190
, pp. 2464-2471
-
-
Sevko, A.1
Michels, T.2
Vrohlings, M.3
-
46
-
-
25144466458
-
Gemcitabine selectively eliminates splenic Gr-1+/CD11b +myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
-
Suzuki E, Kapoor V, Jassar AS,. Gemcitabine selectively eliminates splenic Gr-1+/CD11b +myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11: 6713-21.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 6713-6721
-
-
Suzuki, E.1
Kapoor, V.2
Jassar, A.S.3
-
47
-
-
77951086882
-
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity
-
Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010; 70: 3052-61.
-
(2010)
Cancer Res
, vol.70
, pp. 3052-3061
-
-
Vincent, J.1
Mignot, G.2
Chalmin, F.3
-
48
-
-
79954471164
-
Rgs2 mediates pro-angiogenic function of myeloid derived suppressor cells in the tumor microenvironment via upregulation of MCP-1
-
Boelte KC, Gordy LE, Joyce S,. Rgs2 mediates pro-angiogenic function of myeloid derived suppressor cells in the tumor microenvironment via upregulation of MCP-1. PLoS One 2011; 6: e18534.
-
(2011)
PLoS One
, vol.6
, pp. e18534
-
-
Boelte, K.C.1
Gordy, L.E.2
Joyce, S.3
-
49
-
-
33751531874
-
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function
-
Serafini P, Meckel K, Kelso M,. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006; 203: 2691-702.
-
(2006)
J Exp Med
, vol.203
, pp. 2691-2702
-
-
Serafini, P.1
Meckel, K.2
Kelso, M.3
-
50
-
-
68849128500
-
Therapeutic targeting of myeloid-derived suppressor cells
-
Ugel S, Delpozzo F, Desantis G, et al. Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 2009; 9: 470-81.
-
(2009)
Curr Opin Pharmacol
, vol.9
, pp. 470-481
-
-
Ugel, S.1
Delpozzo, F.2
Desantis, G.3
|